Company Data
Viracta Therapeutics Inc.
Ticker
VIRX
Current Price
$0.0295 -19.95%
Market Cap
$1.2M
Price Target
Refer to Report
Volume
573.2K
52wk Range
$0.008 - $1.31
Overview
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.